Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...
Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
FRANKFURT, GERMANY--(Marketwired - July 22, 2016) - Nobles Medical Technologies II (NMT2) continued to surprise the more than 900 cardiologist and cardiac-specialist attendees at the CSI conference on ...
The Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) has developed an indigenous occlusion device for the non-surgical closure of Atrial Septal Defect (ASD), a congenital ...
Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...
LOS ANGELES, CA--(Marketwired - March 10, 2016) - Dr. Niels Erik Nielsen, Director of Structural Heart Interventions at the Linkoping University Hospital in Linkoping Sweden, successfully performed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results